About Gliolab
A state-of-the-art genomic testing laboratory created by the Glioblastoma Foundation to bring cutting-edge precision medicine to every glioblastoma patient.
About Gliolab
A state-of-the-art genomic testing laboratory created by the Glioblastoma Foundation to bring cutting-edge precision medicine to every glioblastoma patient.
OUR MISSION
Gliolab advances precision oncology for glioblastoma by delivering clinically-validated genomic testing that informs diagnosis, classification, and individualized treatment. We provide diagnostic tests specialized for glioblastoma that support accurate diagnosis and personalized treatment planning.
WHO WE ARE
We provide three essential genomic tests—Whole Genome DNA Methylation Testing, Comprehensive Genomic Profiling, and Gene Fusion Detection—to accurately diagnose and guide treatment for glioblastoma patients.
WHAT SETS US APART?
Founded by a patient
advocacy organization
Our work is mission-driven—
not-for-profit.
Guided by experts
Our molecular tumor board
includes leading neuro-
oncologists, pathologists, and
clinical trials specialists.
Focused solely on glioblastoma
Unlike commercial labs, our
protocols and reporting are
optimized for this specific cancer.
Accessible to all
Our simple payment model
ensures no one is left behind.
Dr. Gita Kwatra, PharmD, MBA
Founder & CEO
LEADERSHIP & ADVISORS
“Precision medicine begins with precision diagnostics.”
At the Glioblastoma Foundation, our mission is to transform the landscape of glioblastoma care through cutting-edge molecular diagnostics. With the establishment of Gliolab, our CLIA-certified Genomic Testing Laboratory, we are committed to providing every patient with access to cutting-edge genomic testing, designed for glioblastoma.
Our dedicated team of experts ensures every test meets the highest standards of accuracy and reliability. Understanding the molecular fingerprint of each tumor enables more personalized, effective therapies.
Thank you for entrusting us with your care.
OUR TEAM
LABORATORY LEADERSHIP
Gita Kwatra, PharmD, MB
CEO
Ferrin Wheeler, PhD, FACMG
Laboratory Director
OPERATIONAL TEAM
Stacey Kauafman
Quality/Regulatory Manager
Chris Younger
General Supervisor
Testing Personnel
Matthew Ahlers
Abraham Jimenez
SCIENTIFIC ADVISORS
Dr. Madan Kwatra, PhD
Duke University
Dr. Kathryn Becker, MD, PhD
University of California-San Diego
Dr. Glenn J. Lesser, MD
Wake Forest University
Dr. Ken Aldape, MD
Mayo Clinic
Dr. Sharona Ben-Haim, MD
UC San Diego Health
certifications & Tests
CLIA Registration
The laboratory is CLIA-registered, ensuring compliance
with federal standards for quality laboratory testing.
[CLIA number: 34D2316424 I NPI number: 1437958824]
OUR COMMITMENT
We are committed to delivering the highest standards in molecular diagnostics so that glioblastoma patients can access the therapies and trials best suited to their tumor biology. Whether you are a physician seeking to improve treatment planning or a patient looking for clarity and direction, we are here to support you on this journey.
